HC Wainwright Reaffirms Buy Rating for Femasys (NASDAQ:FEMY)

by · The Cerbat Gem

Femasys (NASDAQ:FEMY – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $12.00 price target on the stock.

Separately, Chardan Capital cut their price target on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, November 13th.

Read Our Latest Analysis on FEMY

Femasys Price Performance

Shares of Femasys stock traded down $0.02 on Thursday, reaching $1.45. The company’s stock had a trading volume of 6,008,943 shares, compared to its average volume of 268,376. The company has a quick ratio of 3.26, a current ratio of 3.94 and a debt-to-equity ratio of 0.86. The company has a market capitalization of $33.09 million, a P/E ratio of -1.78 and a beta of -2.86. Femasys has a 52-week low of $0.86 and a 52-week high of $2.12. The stock has a 50-day moving average price of $1.30 and a 200-day moving average price of $1.19.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of FEMY. Geode Capital Management LLC boosted its stake in shares of Femasys by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 216,164 shares of the company’s stock valued at $238,000 after buying an additional 9,681 shares during the period. Northern Trust Corp lifted its stake in Femasys by 42.6% in the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after acquiring an additional 37,675 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Femasys in the 4th quarter valued at approximately $45,000. XTX Topco Ltd lifted its stake in Femasys by 123.9% during the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after purchasing an additional 18,004 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Femasys in the 4th quarter valued at $30,000. 65.27% of the stock is owned by institutional investors and hedge funds.

Femasys Company Profile

(Get Free Report)

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.

See Also